Preventing cardiovascular disease in women

American Family Physician

Volumn 74, Issue 8, 2006, Pages 1331-1340

  Hayes, Sharonne N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; WARFARIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HORMONAL THERAPY; HUMAN; LIFESTYLE; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; STROKE; WOMEN'S HEALTH;

ADULT; AGED; CARDIOVASCULAR DISEASES; FAMILY PRACTICE; FEMALE; HUMANS; MIDDLE AGED; PRACTICE GUIDELINES; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 33750205626     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al., for the American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [Published correction appears in Circulation 2006;113:e696]. Circulation 2006;113:e85-151.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
4. Meigs JB, Stafford RS. Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. J Gen Intern Med 2000;15:220-8.
5. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the U.S. population: report from the third National Health and Nutrition examination Survey. Arch Intern Med 2001;161:1621-8.
6. Persell SD, Baker DW. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 2004;164:2492-9.
7. Centers for Disease Control and Prevention. Missed opportunities in preventive counseling for cardiovascular disease - United States, 1995. MMWR Morb Mortal Wkly Rep 1998;47:91-5.
8. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for the HERS Research Group. Adherence to National Cholesterol education Program treatment goals in postmenopausal women with heart disease. the Heart and estrogen/Progestin Replacement Study (HERS). JAMA 1997;277:1281-6.
9. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al., for the CRUSADE Investigators. Gender disparities in the diagnosis and treatment of non-St-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse outcomes With early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005;45:832-7.
10. Mosca L, Ferris A, Fabunmi R, Robertson RM. Tracking women's awareness of heart disease: an American Heart Association national study. Circulation 2004;109:573-9.
11. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
12. Abuful A, Gidron Y, Henkin Y. Physicians' attitudes toward preventive therapy for coronary artery disease: is there a gender bias? Clin Cardiol 2005;28:389-93.
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al., for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
14. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al., for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
15. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al., for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
16. Third Report of the National Cholesterol education Program (NCEP) expert Panel on Detection, evaluation, and treatment of High Blood Cholesterol in Adults (Adult treatment Panel III) final report. Circulation 2002;106:3143-421.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.; Joint National Committee on Prevention, Detection, evaluation, and treatment of High Blood Pressure; National High Blood Pressure education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, evaluation, and treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
18. Bray GA, Vollmer WM, Sacks FM, Obarzanek E, Svetkey LP, Appel LJ, for the DASH Collaborative Research Group. A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium trial. Am J Cardiol 2004;94:222-7.
19. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care 2003;26(suppl 1):S25-7.
20. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on obesity and Heart Disease from the obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
21. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville, Md.: U.S. Department of Health and Human Services Public Health Service, 2000.
22. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/eSC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association task Force on Practice Guidelines and the european Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
23. Gibbons RJ, Smith S, Antman E. American College of Cardiology/American Heart Association clinical practice guidelines: Part I: where do they come from? Circulation 2003;107:2979-86.
24. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
25. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol education Program Adult treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
27. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al., for the Diabetes Control and Complications trial/epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
28. American Diabetes Association. Standards of medical care in diabetes - 2006 [Published correction appears in Diabetes Care 2006;29:1192]. Diabetes Care 2006;29(suppl 1):S4-42.
29. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al., for the Sertraline Antidepressant Heart Attack Randomized trial (SADHEARt) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina [Published correction appears in JAMA 2002;288:1720]. JAMA 2002;288:701-9.
30. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al., for the ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792-8.
31. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart outcomes Prevention evaluation Study Investigators [Published corrections appear in N Engl J Med 2000;342:748, 1376]. N Engl J Med 2000;342:145-53.
32. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
33. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
34. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials [Published correction appears in JAMA 2006;295:2002]. JAMA 2006;295:306-13.
35. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001;103:2365-70.
36. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005;112:1687-91.
37. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004;94:889-94.
38. Mosca L. Cardiology patient page. Heart disease prevention in women. American Heart Association. Circulation 2004;109:e158-60.
39. Johnson PA, Manson JE. Cardiology patient page. How to make sure the beat goes on: protecting a woman's heart. Circulation 2005;111:e28-33.